MK 8242
Alternative Names: MK-8242; SCH 900242Latest Information Update: 02 Oct 2021
At a glance
- Originator Merck & Co
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-mdm2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia in USA (PO, Capsule)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in USA (PO, Capsule)
- 01 Mar 2015 Merck Sharp & Dohme completes a phase I trial in Solid tumour in USA (NCT01463696)